Resumen de Haemolytic uraemic syndrome associated with gemcitabine

Irene Moya Horno, Rosa Querol Niñerola, Teresa Bonfill Abella, Elsa Dalmau Pórtulas, Enrique Gallardo-Díaz, Eugeni Saigí Grau, Carles Pericay Pijaume

• Haemolytic uraemic syndrome (HUS) is a rare thromboembolic complication observed in patients with cancer. It is characterised by the clinical triad of acute renal failure, microangiopathic haemolytic anaemia and thrombocytopaenia. It may be associated with a variety of aetiologies, including chemotherapeutic agents such as mitomycin, cisplatin, bleomycin, 5-fluorouracil and, most recently, gemcitabine. We report a 70-year-old patient treated with gemcitabine who developed haemolytic uraemic syndrome.